Paclitaxel formulations: Challenges and novel delivery options

Current Drug Delivery

Volumn 11, Issue 6, 2014, Pages 666-686

  Nehate, Chetan ^a,b   Jain, Sharad ^a,b   Saneja, Ankit ^a   Khare, Vaibhav ^a   Alam, Noor ^a   Dubey, Ravindra Dhar ^a   Gupta, Prem N ^a  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Cancer; Drug delivery systems; Liposomes; Nanoparticles; Paclitaxel

Indexed keywords

BETA TUBULIN; CARBOPLATIN; CREMOPHOR; CYCLODEXTRIN; CYCLOPHOSPHAMIDE; DENDRIMER; DRUG SOLVENT; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NANOPARTICLE; PACLITAXEL; SARGRAMOSTIM; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; NANOMATERIAL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DISTRIBUTION HALF-LIFE; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; EMULSION; HUMAN; IMPLANT; INFECTION; MICELLIZATION; MYALGIA; NANOENCAPSULATION; NEPHROTOXICITY; NEUROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; MEDICINAL CHEMISTRY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NANOSTRUCTURES; NEOPLASMS; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84924989806     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201811666140609154949     Document Type: Article

References (208)

1. Koudelka, S.; Turanek, J. Liposomal paclitaxel formulations. J. Control. Release, 2012, 163, 322-334.
2. Spratlin, J.; Sawyer, M.B. Pharmacogenetics of paclitaxel metabolism. Crit. Rev. Oncol. Hematol., 2007, 61, 222-229.
3. Zhang, Z.; Mei, L.; Feng, S.S. Paclitaxel drug delivery systems. Expert Opin. Drug Deliv., 2013, 10, 325-340.
4. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 1971, 93, 2325-2327.
5. Spencer, C. M.; Faulds, D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 1994, 48(5), 794-847.
6. Horwitz, S.B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H. J.; Yang, C. Taxol: mechanisms of action and resistance. J. Natl. Cancer Inst. Monogr.,1993, 55-61.
7. Manfredi, J.J.; Parness, J.; Horwitz, S.B. Taxol binds to cellular microtubules. J. Cell Biol., 1982, 94, (3), 688-696.
8. Schiff, P.B.; Horwitz, S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U.S.A., 1980, 77, 1561-1565.
9. Xu, K.; Ludueña, R. F. Characterization of nuclear βII-tubulin in tumor cells: A possible novel target for taxol. Cell. Motil. Cytoskeleton, 2002, 53, 39-52.
10. Haldar, S.; Chintapalli, J.; Croce, C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 1996, 56, 1253-1255.
11. Veldhoen, R.A.; Banman, S.L.; Hemmerling, D.R.; Odsen, R.; Simmen, T.; Simmonds, A.J.; Underhill, D.A.; Goping, I.S. The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene, 2013, 32, 736-746.
12. Swindell, C.S.; Krauss, N.E.; Horwitz, S.B.; Ringel, I. Biologically active taxol analogs with deleted A-ring side chain substituents and variable C-2'configurations. J. Med. Chem., 1991, 34, 1176-1184.
13. Panchagnula, R. Pharmaceutical aspects of paclitaxel. Int. J. Pharm., 1998, 172, 1-15.
14. Suffness, M. In: Annual Reports in Medicinal Chemistry, James, A.B., Ed.; Academic Press, 1993; Vol. 28, pp. 305-314.
15. Kingston, D. G. I. Taxol: the chemistry and structure-activity relationships of a novel anticancer agent. Trends Biotechnol., 1994, 12, 222-227.
16. Kumar, G.; Walle, U.; Bhalla, K.; Walle, T. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res. Commun. Chem. Pathol. Pharmacol., 1993, 80, 337-344.
17. Sonnichsen, D.; Relling, M. Clinical pharmacokinetics of paclitaxel. Clin. Pharmacokinet., 1994, 27, 256-269.
18. Fellner, S.; Bauer, B.; Miller, D. S.; Schaffrik, M.; Fankhanel, M.; Spruß, T.; Bernhardt, G.; Graeff, C.; Farber, L.; Gschaidmeier, H. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest., 2002, 110, 1309-1318.
19. Cresteil, T.; Monsarrat, B.; Alvinerie, P.; Treluyer, J. M.; Vieira, I.; Wright, M. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res., 1994, 54, (2), 386-392.
20. Van Tellingen, O.; Huizing, M.; Panday, V. N.; Schellens, J.; Nooijen, W.; Beijnen, J. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br. J. Cancer, 1999, 81, 330-335.
21. Sparreboom, A.; van Zuylen, L.; Brouwer, E.; Loos, W.J.; de Bruijn, P.; Gelderblom, H.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood. Cancer Res., 1999, 59, 1454-1457.
22. Kim, T.-Y.; Kim, D.W.; Chung, J.Y.; Shin, S.G.; Kim, S.C.; Heo, D.S.; Kim, N.K.; Bang, Y.J. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res., 2004, 10, 3708-3716.
23. Feng, S.S.; Huang, G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J. Control. Release, 2001, 71, 53-69.
24. Dhanikula, A.B.; Panchagnula, R. Localized paclitaxel delivery. Int. J. Pharm., 1999, 183, 85-100.
25. Xie, J.; Wang, C. H. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm. Res., 2005, 22, 2079-2090.
26. Bhardwaj, V.; Ankola, D.; Gupta, S.; Schneider, M.; Lehr, C.M.; Kumar, M. N. R. PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm. Res., 2009, 26, 2495-2503.
27. Rowinsky, E.K.; Cazenave, L.A.; Donehower, R.C. Taxol: A novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 1990, 82, 1247-1259.
28. Weiss, R. B.; Donehower, R.; Wiernik, P.; Ohnuma, T.; Gralla, R.; Trump, D.; Baker, J.; Van Echo, D.; Von Hoff, D.; Leyland-Jones, B. Hypersensitivity reactions from taxol. J. Clin. Oncol., 1990, 8, 1263-1268.
29. Fjällskog, M. L.; Frii, L.; Bergh, J. Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet, 1993, 342, 873.
30. Van Zuylen, L.; Verweij, J.; Sparreboom, A., Role of formulation vehicles in taxane pharmacology. Invest. New Drugs, 2001, 19(2), 125-141.
31. Wood, A. J.; Rowinsky, E. K.; Donehower, R. C. Paclitaxel (taxol). N. Engl. J. Med., 1995, 332 (15), 1004-1014.
32. Szebeni, J.; Alving, C. R.; Muggia, F. M. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study. J. Natl. Cancer Inst., 1998, 90, 300-306.
33. Weiszhar, Z.; Czucz, J.; Revesz, C.; Rosivall, L.; Szebeni, J.; Rozsnyay, Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. Sci., 2012, 45 (4), 492-498.
34. He, L.; Wang, G. L.; Zhang, Q. An alternative paclitaxel microemulsion formulation: hypersensitivity evaluation and pharmacokinetic profile. Int. J. Pharm., 2003, 250 (1), 45-50.
35. Michaud, L. Methods for preventing reactions secondary to Cremophor EL. Ann. Pharmacother., 1997, 31, 1402-1404.
36. Essayan, D. M.; Kagey-Sobotka, A.; Colarusso, P. J.; Lichtenstein, L.M.; Ozols, R.F.; King, E. D. Successful parenteral desensitization to paclitaxel. J. Allergy Clin. Immunol., 1996, 97 (1), 42-46.
37. Sheihet, L.; Garbuzenko, O. B.; Bushman, J.; Gounder, M. K.; Minko, T.; Kohn, J. Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor. Eur. J. Pharm. Sci., 2012, 45 (3), 320-329.
38. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 2001, 37(13), 1590-1598.
39. Ten Tije, A. J.; Verweij, J.; Loos, W. J.; Sparreboom, A. Pharmacological effects of formulation vehicles : Implications for cancer chemotherapy. Clin. Pharmacokinet., 2003, 42(7), 665-685.
40. Besarab, A.; Jarrell, B. E.; Hirsch, S.; Carabasi, R. A.; Cressman, M. D.; Green, P. Use of the isolated perfused kidney model to assess the acute pharmacologic effects of cyclosporine and its vehicle, cremophor EL. Transplantation, 1987, 44(2), 195-201.
41. Podratz, J.L.; Windebank, A.J. Dialyzer associated neurotoxicity due to a change in fatty acid structure. Trans. Am. Soc. Neurochem., 1993, 24, 229.
42. Mielke, S.; Sparreboom, A.; Mross, K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur. J. Cancer, 2006, 42, 24-30.
43. Marupudi, N. I.; Han, J. E.; Li, K. W.; Renard, V. M.; Tyler, B. M.; Brem, H. Paclitaxel: A review of adverse toxicities and novel delivery strategies. Expert Opin. Drug Saf., 2007,6, 609-621.
44. Mielke, S.; Mross, K.; Gerds, T. A.; Schmidt, A.; Wäsch, R.; Berger, D. P.; Lange, W.; Behringer, D. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs, 2003, 14, 785-792.
45. Theiss, C.; Meller, K. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res., 2000, 299, 213-224.
46. Scuteri, A.; Nicolini, G.; Miloso, M.; Bossi, M.; Cavaletti, G.; Windebank, A. J.; Tredici, G. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res., 2006, 26, 1065-1070.
47. Gornstein, E.; Schwarz, T. L. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology, 2014, 76, 175-183.
48. Ibrahim, N. K.; Desai, N.; Legha, S.; Soon-Shiong, P.; Theriault, R. L.; Rivera, E.; Esmaeli, B.; Ring, S. E.; Bedikian, A.; Hortobagyi, G. N. Phase I and pharmacokinetic study of ABI-007, a Cremophor- free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res., 2002, 8, 1038-1044.
49. Argyriou, A.; Chroni, E.; Koutras, A.; Ellul, J.; Papapetropoulos, S.; Katsoulas, G.; Iconomou, G.; Kalofonos, H. Vitamin E for prophylaxis against chemotherapy-induced neuropathy A randomized controlled trial. Neurology, 2005, 64, 26-31.
50. Rabah, S. O., Acute Taxol nephrotoxicity: Histological and ultrastructural studies of mice kidney parenchyma. Saudi. J. Biol. Sci. 2010, 17(2), 105-114.
51. Rowinsky, E. K.; McGuire, W.; Guarnieri, T.; Fisherman, J.; Christian, M.; Donehower, R. Cardiac disturbances during the administration of taxol. J. Clin. Oncol., 1991, 9, 1704-1712.
52. Minotti, G.; Saponiero, A.; Licata, S.; Menna, P.; Calafiore, A. M.; Teodori, G.; Gianni, L., Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin. Cancer Res., 2001, 7, 1511-1515.
53. Floyd, J. D.; Nguyen, D. T.; Lobins, R. L.; Bashir, Q.; Doll, D. C.; Perry, M. C., Cardiotoxicity of cancer therapy. J. Clin. Oncol. 2005, 23 (30), 7685-7696.
54. Schimmel, K. J.; Richel, D. J.; van den Brink, R. B.; Guchelaar, H. J., Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev., 2004, 30, (2), 181-191.
55. Eisenhauer, E. A.; ten Bokkel Huinink, W.; Swenerton, K. D.; Gianni, L.; Myles, J.; Van der Burg, M.; Kerr, I.; Vermorken, J. B.; Buser, K.; Colombo, N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J. Clin. Oncol., 1994, 12, 2654-2666.
56. Lang, P. A.; Huober, J.; Bachmann, C.; Kempe, D. S.; Sobiesiak, M.; Akel, A.; Niemoeller, O.; Dreischer, P.; Eisele, K.; Klarl, B. A. Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel. Cell Physiol. Biochem., 2006, 18, 151-164.
57. Casasnovas, R. O.; Haioun, C.; Dumontet, C.; Gabarre, J.; Richard, B.; Lederlin, P.; Caillot, D.; Stamatoullas, A.; Morel, P.; Quesnel, B.; Blay, J. Y.; Bouabdallah, K.; Gisselbrecht, C., Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Haematologica, 2000, 85 (5), 502-507.
58. Jacobson, S.D.; Loprinzi, C.L.; Sloan, J.A.; Wilke, J.L.; Novotny, P.J.; Okuno, S.H.; Jatoi, A.; Moynihan, T.J. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J. Support. Oncol., 2003, 1(4), 274-278.
59. Rowinsky, E.K.; Chaudhry, V.; Forastiere, A.A.; Sartorius, S.E.; Ettinger, D.S.; Grochow, L.B.; Lubejko, B.G.; Cornblath, D.R.; Donehower, R.C. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol., 1993, 11, 2010-2020.
60. Singla, A.K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharm., 2002, 235, 179-192.
61. Saneja, A.; Khare, V.; Alam, N.; Dubey, R. D.; Gupta, P. N. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: Pharmacokinetic perspective and clinical relevance. Expert Opin. Drug Deliv., 2014, 11(1), 121-38.
62. Shono, Y.; Nishihara, H.; Matsuda, Y.; Furukawa, S.; Okada, N.; Fujita, T.; Yamamoto, A. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J. Pharm. Sci., 2004, 93 (4), 877-85.
63. Sosnik, A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing "Generally Recognized As Safe" (GRAS) nanopharmaceuticals: A review. Adv. Drug Deliv. Rev., 2013, 65 (13-14), 1828-51.
64. Adams, J.D.; Flora, K.; Goldspiel, B.; Wilson, J.; Arbuck, S.; Finley, R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr., 1993, 141-147.
65. Waugh, W.N.; Trissel, L.A.; Stella, V.J. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am. J. Hosp. Pharm., 1991, 48, 1520-1524.
66. Xu, Q.A.; Trissel, L.A.; Zhang, Y. Paclitaxel Compatibility with IV Express Filter Unit. Int. J. Pharm. Comp., 1998, 2, 243-245.
67. Donyai, P.; Sewell, G. J. Physical and chemical stability of paclitaxel infusions in different container types. J. Oncol. Pharm. Pract., 2006, 12, 211-222.
68. Rubino JP. In: Encyclopedia of pharmaceutical technology; Swarbrick J, Ed.Informa Healthcare: New York, 2007; pp. 806-819.
69. Mojaverian, P.; Repta, A. Development of an intravenous formulation for the unstable investigational cytotoxic nucleosides 5-azacytosine arabinoside (NSC 281272) and 5-azacytidine (NSC 102816). J. Pharm. Pharmacol., 1984, 36, 728-733.
70. Connors, K. A.; Amidon, G. L.; Stella, V. J. Chemical stability of pharmaceuticals: A handbook for pharmacists. Wiley & Sons: New York, 1986.
71. Flynn, G. L. Solubility concepts and their applications to the formulation of pharmaceutical systems. Part I. Theoretical foundations. J. Parenter. Sci. Technol., 1984, 38, 202-209.
72. Bissery, M. C.; Guénard, D.; Guéritte-Voegelein, F.; Lavelle, F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res., 1991, 51, 4845-4852.
73. Tarr, B. D.; Yalkowsky, S. H. A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J. Parenter. Sci. Technol., 1987, 41, 31-33.
74. Nornoo, A. O.; Zheng, H.; Lopes, L. B.; Johnson-Restrepo, B.; Kannan, K.; Reed, R. Oral microemulsions of paclitaxel: In situ and pharmacokinetic studies. Eur. J. Pharm. Biopharm., 2009, 71, 310-317.
75. Yang, S.; Gursoy, R. N.; Lambert, G.; Benita, S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res., 2004, 21, 261-270.
76. Jing, X.; Deng, L.; Gao, B.; Xiao, L.; Zhang, Y.; Ke, X.; Lian, J.; Zhao, Q.; Ma, L.; Yao, J., A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel. Nanomedicine: Nanotechnol. Biol. Med., 2014, 10, 371-380.
77. Xia, X.-J.; Guo, R.-F.; Liu, Y.-L.; Zhang, P.-X.; Zhou, C.-P.; Jin, D.- J.; Wang, R.-Y., Formulation, characterization and hypersensitivity evaluation of an intravenous emulsion loaded with a paclitaxelcholesterol complex. Chem. Pharm. Bull., 2011, 5(3), 321-326.
78. Swarbick, J. Micellization, Liquid Oral Preparations. In Encyclopedia of Pharmaceutical Technology, third ed.; 2007; Vol. 1, p 2222.
79. Yokoyama, M.; Miyauchi, M.; Yamada, N.; Okano, T.; Sakurai, Y.; Kataoka, K.; Inoue, S. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycinconjugated poly (ethylene glycol)-poly (aspartic acid) block copolymer. Cancer Res., 1990, 50, 1693-1700.
80. Abouzeid, A. H.; Patel, N. R.; Torchilin, V. P., Polyethylene Glycol-Phosphatidylethanolamine (PEG-PE)/Vitamin E Micelles for Co-Delivery of Paclitaxel and Curcumin to Overcome Multi-Drug Resistance in Ovarian Cancer. Int. J. Pharm., 2014, 464, 178-184.
81. Nam, J.-P.; Park, S.-C.; Kim, T.-H.; Jang, J.-Y.; Choi, C.; Jang, M.-K.; Nah, J.-W., Encapsulation of paclitaxel into lauric acid carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery. Int. J. Pharm., 2013, 457, (1), 124-135.
82. Yao, H.J.; Ju, R.J.; Wang, X.X.; Zhang, Y.; Li, R.J.; Yu, Y.; Zhang, L.; Lu, W.L. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials, 2011, 32, 3285-3302.
83. Huh, K.M.; Lee, S.C.; Cho, Y.W.; Lee, J.; Jeong, J.H.; Park, K. Hydrotropic polymer micelle system for delivery of paclitaxel. J. Control. Release, 2005, 101, 59-68.
84. Huh, K. M.; Min, H. S.; Lee, S. C.; Lee, H. J.; Kim, S.; Park, K. A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J. Control. Release, 2008, 126, 122-129.
85. Burt, H. M.; Zhang, X.; Toleikis, P.; Embree, L.; Hunter, W. L. Development of copolymers of poly (D, L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf. B. Biointerfaces, 1999, 16, 161-171.
86. Shuai, X.; Merdan, T.; Schaper, A. K.; Xi, F.; Kissel, T. Corecross- linked polymeric micelles as paclitaxel carriers. Bioconjug. Chem., 2004, 15, 441-448.
87. Wang, J.; Mongayt, D.; Torchilin, V. P. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly (ethylene glycol)-lipid conjugate and positively charged lipids. J. Drug Target, 2005, 13, 73-80.
88. Kim, S. C.; Kim, D. W.; Shim, Y. H.; Bang, J. S.; Oh, H. S.; Wan Kim, S.; Seo, M. H. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J. Control. Release, 2001, 72, 191-202.
89. Cho, Y. W.; Lee, J.; Lee, S. C.; Huh, K. M.; Park, K. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles. J. Control. Release, 2004, 97, 249-257.
90. Shin, H. C.; Alani, A. W.; Rao, D. A.; Rockich, N. C.; Kwon, G. S. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Release, 2009, 140, 294-300.
91. Wei, Z.; Hao, J.; Yuan, S.; Li, Y.; Juan, W.; Sha, X.; Fang, X. Paclitaxel-loaded Pluronic P123/F127 mixed polymeric micelles: formulation, optimization and in vitro characterization. Int. J. Pharm., 2009, 376, 176-185.
92. Dabholkar, R. D.; Sawant, R. M.; Mongayt, D. A.; Devarajan, P. V.; Torchilin, V. P. Polyethylene glycol–phosphatidylethanolamine conjugate (PEG–PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int. J. Pharm., 2006, 315, 148-157.
93. Cai, S.; Vijayan, K.; Cheng, D.; Lima, E. M.; Discher, D. E. Micelles of different morphologies—advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery. Pharm. Res., 2007, 24, 2099-2109.
94. Musacchio, T.; Laquintana, V.; Latrofa, A.; Trapani, G.; Torchilin, V. P. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: Synergistic anticancer effect. Mol. Pharm. 2008, 6, 468-479.
95. Zhang, C.; Qineng, P.; Zhang, H., Self-assembly and characterization of paclitaxel-loaded N-octyl-O-sulfate chitosan micellar system. Colloids Surf. B Biointerfaces, 2004, 39, 69-75.
96. You, J.; Hu, F.-Q.; Du, Y.-Z.; Yuan, H. Polymeric micelles with glycolipid-like structure and multiple hydrophobic domains for mediating molecular target delivery of paclitaxel. Biomacromolecules, 2007, 8, 2450-2456.
97. Zhu, C.; Jung, S.; Luo, S.; Meng, F.; Zhu, X.; Park, T. G.; Zhong, Z. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA–PCL–PDMAEMA triblock copolymers. Biomaterials, 2010, 31, 2408-2416.
98. Soga, O.; van Nostrum, C. F.; Fens, M.; Rijcken, C. J.; Schiffelers, R. M.; Storm, G.; Hennink, W. E. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J. Control Release, 2005, 103, 341-354.
99. Li, Y.; Xu, X.; Shen, Y.; Qian, C.; Lu, F.; Guo, S. Preparation and evaluation of copolymeric micelles with high paclitaxel contents and sustained drug release. Colloids Surf. A. Physicochem. Eng. Asp., 2013, 429, 12-18.
100. Tao, Y.; Han, J.; Wang, X.; Dou, H. Nano-formulation of Paclitaxel by Vitamin E succinate Functionalized Pluronic Micelles for Enhanced Encapsulation, Stability and Cytotoxicity. Colloids and Surfaces B: Biointerfaces, 2013, 102, 604-610.
101. Wang, F.; Shen, Y.; Xu, X.; Lv, L.; Li, Y.; Liu, J.; Li, M.; Guo, A.; Guo, S.; Jin, F. Selective tissue distribution and long circulation endowed by paclitaxel loaded PEGylated poly(epsiloncaprolactone- co-L-lactide) micelles leading to improved anti-tumor effects and low systematic toxicity. Int. J. Pharm., 2013, 456(1), 101-112.
102. Slingerland, M.; Guchelaar, H.-J.; Gelderblom, H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov. Today, 2012, 17, 160-166.
103. Allen, T. M.; Cheng, W. W.; Hare, J. I.; Laginha, K. M. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med. Chem., 2006, 6, 513-523.
104. Sharma, A.; Mayhew, E.; Straubinger, R. M. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res., 1993, 53, 5877-5881.
105. Immordino, M. L.; Dosio, F.; Cattel, L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed., 2006, 1, 297-315.
106. Boulikas, T., Clinical overview on Lipoplatin™: A successful liposomal formulation of cisplatin. Expert Opin. Investig. Drugs, 2009, 18, 1197-1218.
107. Crosasso, P.; Ceruti, M.; Brusa, P.; Arpicco, S.; Dosio, F.; Cattel, L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J. Control Release, 2000, 63, 19-30.
108. Huang, Y.; Chen, X. M.; Zhao, B. X.; Ke, X. Y.; Zhao, B. J.; Zhao, X.; Wang, Y.; Zhang, X.; Zhang, Q. Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): In vitro and in vivo. AAPs. Pharm. Sci. Tech., 2010, 11, 752-759.
109. Latimer, P.; Menchaca, M.; Snyder, R. M.; Yu, W.; Gilbert, B. E.; Sanders, B. G.; Kline, K. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp. Biol. Med. (Maywood), 2009, 234, 1244-1252.
110. Wu, J.; Liu, Q.; Lee, R. J. A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm., 2006, 316, 148-153.
111. Yang, T.; Choi, M. K.; Cui, F. D.; Lee, S. J.; Chung, S. J.; Shim, C. K.; Kim, D. D. Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm. Res., 2007, 24, 2402-2411.
112. Meng, S.; Su, B.; Li, W.; Ding, Y.; Tang, L.; Zhou, W.; Song, Y.; Caicun, Z. Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Med. Oncol., 2011, 28, 1180-1187.
113. Strieth, S.; Eichhorn, M. E.; Werner, A.; Sauer, B.; Teifel, M.; Michaelis, U.; Berghaus, A.; Dellian, M. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin. Clin. Cancer Res., 2008, 14, 4603-4611.
114. Cosco, D.; Paolino, D.; Maiuolo, J.; Russo, D.; Fresta, M. Liposomes as multicompartmental carriers for multidrug delivery in anticancer chemotherapy. Drug Deliv. Transl., Res., 2011, 1, 66-75.
115. Zhao, P.; Wang, H.; Yu, M.; Cao, S.; Zhang, F.; Chang, J.; Niu, R. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: In vitro and in vivo evaluation. Pharm. Res., 2010, 27, 1914-1926.
116. Utreja, P.; Jain, S.; Tiwary, A. Localized delivery of paclitaxel using elastic liposomes: Formulation development and evaluation. Drug Deliv., 2011, 18, 367-376.
117. Yang, T.; Cui, F.-D.; Choi, M. K.; Lin, H.; Chung, S. J.; Shim, C. K.; Kim, D. D., Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv., 2007, 14, 301-308.
118. Yoshizawa, Y.; Kono, Y.; Ogawara, K. I..; Kimura, T.; Higaki, K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm., 2011, 412, 132-141.
119. Zhao, L.; Ye, Y.; Li, J.; Wei, Y. M. Preparation and the in[1]vivo evaluation of paclitaxel liposomes for lung targeting delivery in dogs. J. Pharm. Pharmacol., 2011, 63, 80-86.
120. Zhao, H.; Wang, J.-C.; Sun, Q.-S.; Luo, C.-L.; Zhang, Q. RGDbased strategies for improving antitumor activity of paclitaxelloaded liposomes in nude mice xenografted with human ovarian cancer. J. Drug Target., 2009, 17, 10-18.
121. Nie, S.; Hsiao, W. W.; Pan, W.; Yang, Z. Thermoreversible Pluronic® F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: In vitro drug release, cell cytotoxicity, and uptake studies. Int. J. Nanomed., 2011, 6, 151-166.
122. Chen, D.; Jiang, X.; Huang, Y.; Zhang, C.; Ping, Q. pH-sensitive mPEG-Hz-cholesterol conjugates as a liposome delivery system. J. Bioact. Compat. Polym., 2010, 25, 527-542.
123. Yan, F.; Li, L.; Deng, Z.; Jin, Q.; Chen, J.; Yang, W.; Yeh, C. K.; Wu, J.; Shandas, R.; Liu, X. Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers. J. Control. Release, 2013, 166, 246-255.
124. Mo, Y.; Lim, L.-Y. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J. Control Release, 2005, 108(2), 244-262.
125. Uekama, K.; Narisawa, S.; Hirayama, F.; Otagiri, M. Improvement of dissolution and absorption characteristics of benzodiazepines by cyclodextrin complexation. Int. J. pharm., 1983, 16(3), 327-338.
126. Uekama, K.; Fujinaga, T.; Hirayama, F.; Otagiri, M.; Yamasaki, M.; Seo, H.; Hashimoto, T.; Tsuruoka, M. Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. J. Pharm. Sci., 1983, 72, (11), 1338-1341.
127. Estes, K.; Brewster, M.; Webb, A.; Bodor, N. A non-surfactant formulation for alfaxalone based on an amorphous cyclodextrin: Activity studies in rats and dogs. Int. J. Pharm., 1990, 65 (1), 101-107.
128. Hirayama, F.; Uekama, K. Cyclodextrin-based controlled drug release system. Advanced drug delivery reviews 1999, 36, (1), 125-141.
129. Fonseca, C.; Simoes, S.; Gaspar, R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release, 2002, 83, 273-286.
130. Kollipara, S.; Bende, G.; Movva, S.; Saha, R. Application of rotatable central composite design in the preparation and optimization of poly (lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev. Ind. Pharm., 2010, 36, 1377-1387.
131. Roy, A.; Singh, M. S.; Upadhyay, P.; Bhaskar, S. Combined chemo-immunotherapy as a prospective strategy to combat cancer: A nanoparticle based approach. Mol. Pharm., 2010, 7, 1778-1788.
132. Chakravarthi, S. S.; De, S.; Miller, D. W.; Robinson, D. H. Comparison of anti-tumor efficacy of paclitaxel delivered in nano-and microparticles. Int. J. Pharm., 2010, 383, 37-44.
133. Xie, J.; Lim, L. K.; Phua, Y.; Hua, J.; Wang, C. H. Electrohydrodynamic atomization for biodegradable polymeric particle production. J. Colloid Interface Sci., 2006, 302, 103-112.
134. Mu, L.; Feng, S. Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J. Control. Release, 2001, 76, 239-254.
135. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28, 869-876.
136. Roy, A.; Singh, M. S.; Upadhyay, P.; Bhaskar, S. Nanoparticle mediated co-delivery of Paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response at the tumor microenvironment in mouse model. Int. J. Pharm., 2013, 445, 171-180.
137. Smitha, K.T.; Anitha, A.; Furuike, T.; Tamura, H.; Nair, S.V.; Jayakumar, R. In vitro evaluation of paclitaxel loaded amorphous chitin nanoparticles for colon cancer drug delivery. Colloids Surf. B. Biointerfaces, 2013, 104, 245-253.
138. Koo, H.; Min, K.H.; Lee, S. C.; Park, J.H.; Park, K.; Jeong, S.Y.; Choi, K.; Kwon, I.C.; Kim, K. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery. J. Control. Release., 2013, 172 (3), 823-831.
139. Bernabeu, E.; Helguera, G.; Legaspi, M. J.; Gonzalez, L.; Hocht, C.; Taira, C.; Chiappetta, D. A. Paclitaxel-loaded PCL-TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane. Colloids Surf. B Biointerfaces, 2014, 113, 43-50.
140. Cserháti, T.; Forgács, E.; Holló, J., Interaction of taxol and other anticancer drugs with α-cyclodextrin. J. Pharm. Biomed. Anal. 1995, 13(4), 533-541.
141. Sharma, U.S.; Balasubramanian, S.V.; Straubinger, R.M. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci., 1995, 84(10), 1223-1230.
142. Dordunoo, S. K.; Burt, H. M. Solubility and stability of taxol: effects of buffers and cyclodextrins. Int. J. Pharm., 1996, 133(1), 191-201.
143. He, H.; Chen, S.; Zhou, J.; Dou, Y.; Song, L.; Che, L.; Zhou, X.; Chen, X.; Jia, Y.; Zhang, J. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials, 2013, 34, 5344-5358.
144. Sahoo, S. K.; Labhasetwar, V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm., 2005, 2, 373-383.
145. Zhan, C.; Gu, B.; Xie, C.; Li, J.; Liu, Y.; Lu, W. Cyclic RGD conjugated poly (ethylene glycol)-co-poly (lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control. Release, 2010, 143, 136-142.
146. Liang, C.; Yang, Y.; Ling, Y.; Huang, Y.; Li, T.; Li, X. Improved therapeutic effect of folate-decorated PLGA–PEG nanoparticles for endometrial carcinoma. Bioorg. Med. Chem., 2011, 19, 4057-4066.
147. Kuo, W. S.; Ku, Y. C.; Sei, H. T.; Cheng, F. Y.; Yeh, C. S. Paclitaxel- loaded stabilizer-free poly (d, l-lactide-co-glycolide) nanoparticles conjugated with quantum dots for reversion of anti-cancer drug resistance and cancer cellular imaging. J. Chin. Chem. Soc., 2009, 56, 923-934.
148. Wang, C.; Ho, P. C.; Lim, L. Y., Wheat germ agglutininconjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells. Int. J. Pharm., 2010, 400, 201-210.
149. Danhier, F.; Vroman, B.; Lecouturier, N.; Crokart, N.; Pourcelle, V.; Freichels, H.; Jérôme, C.; Marchand-Brynaert, J.; Feron, O.; Préat, V. Targeting of tumor endothelium by RGD-grafted PLGAnanoparticles loaded with paclitaxel. J. Control. Release, 2009, 140, 166-173.
150. Tong, R.; Yala, L.; Fan, T. M.; Cheng, J. The formulation of aptamer- coated paclitaxel–polylactide nanoconjugates and their targeting to cancer cells. Biomaterials, 2010, 31, 3043-3053.
151. Ateh, D. D.; Leinster, V. H.; Lambert, S. R.; Shah, A.; Khan, A.; Walklin, H. J.; Johnstone, J. V.; Ibrahim, N. I.; Kadam, M. M.; Malik, Z. The intracellular uptake of CD95 modified paclitaxelloaded poly (lactic-co-glycolic acid) microparticles. Biomaterials, 2011, 32, 8538-8547.
152. Mo, Y.; Lim, L.-Y., Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J. Control. Release, 2005, 107, 30-42.
153. Kou, G.; Gao, J.; Wang, H.; Chen, H.; Li, B.; Zhang, D.; Wang, S.; Hou, S.; Qian, W.; Dai, J. Preparation and characterization of paclitaxel- loaded PLGA nanoparticles coated with cationic SM5-1 single- chain antibody. J. Biochem. Mol. Biol., 2007, 40, 731-739.
154. Lu, J.; Jackson, J. K.; Gleave, M. E.; Burt, H. M. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother. Pharmacol., 2008, 61, 997-1005.
155. Cui, Y.; Xu, Q.; Chow, P. K.; Wang, D.; Wang, C. H. Transferrinconjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials, 2013, 34(33), 8511-8520.
156. Bouquet, W.; Ceelen, W.; Fritzinger, B.; Pattyn, P.; Peeters, M.; Remon, J. P.; Vervaet, C. Paclitaxel/β-cyclodextrin complexes for hyperthermic peritoneal perfusion–Formulation and stability. Eur. J. Pharm Biopharm., 2007, 66, 391-397.
157. Hamada, H.; Ishihara, K.; Masuoka, N.; Mikuni, K.; Nakajima, N. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins. J. Biosci. Bioeng., 2006, 102, 369-371.
158. Liu, Y.; Chen, G.-S.; Li, L.; Zhang, H.-Y.; Cao, D. X.; Yuan, Y. J., Inclusion complexation and solubilization of paclitaxel by bridged bis (β-cyclodextrin) s containing a tetraethylenepentaamino spacer. J. Med. Chem., 2003, 46, 4634-4637.
159. Agüeros, M.; Ruiz-Gatón, L.; Vauthier, C.; Bouchemal, K.; Espuelas, S.; Ponchel, G.; Irache, J. Combined hydroxypropyl-β- cyclodextrin and poly (anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur. J. Pharm. Sci., 2009, 38, 405-413.
160. Bilensoy, E.; Gürkaynak, O.; Doğan, A. L.; Hıncal, A. A. Safety and efficacy of amphiphilic ß-cyclodextrin nanoparticles for paclitaxel delivery. Int. J. Pharm., 2008, 347, 163-170.
161. Ansari, K.A.; J Torne, S.; Vavia, P.R.; Trotta, F.; Cavalli, R. Paclitaxel loaded nanosponges: In-vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr. Drug Deliv., 2011, 8, 194-202.
162. Zhang, X.N.; Tang, L.H.; Yan, X.Y.; Zhang, Q. Solubilization of hydropropyl-beta-cyclodextrin to paclitaxel and its relative molecular inclusion mechanism. Chin. Trad. Herb. Drug, 2007, 38, 1317-1319.
163. Agueros, M.; Zabaleta, V.; Espuelas, S.; Campanero, M.; Irache, J. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly (anhydride) nanoparticles. J. Control. Release, 2010, 145, 2-8.
164. Mukherjee, S.; Ray, S.; Thakur, R. S. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Ind. J. Pharm. Sci., 2009, 71, 349-358.
165. Miao, J.; Du, Y.-Z.; Yuan, H.; Zhang, X.-g.; Hu, F. Q. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf. B. Biointerfaces, 2013, 110, 74-80.
166. Zhang, Y. L.; Zhang, Z. H.; Jiang, T. Y.; Lv, H. X.; Zhou, J. P. Cell uptake of paclitaxel solid lipid nanoparticles modified by cellpenetrating peptides in A549 cells. Pharmazie, 2013, 68, 47-53.
167. Li, R.; Eun, J. S.; Lee, M. K. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch. Pharm. Res., 2011, 34, 331-337.
168. Bansal, T.; Akhtar, N.; Jaggi, M.; Khar, R. K.; Talegaonkar, S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today, 2009, 14, 1067-1074.
169. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev., 2005, 57, 2215-2237.
170. Teow, H. M.; Zhou, Z.; Najlah, M.; Yusof, S. R.; Abbott, N. J.; D'Emanuele, A. Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int. J. Pharm., 2013, 441,701-711.
171. Saad, M.; Garbuzenko, O. B.; Ber, E.; Chandna, P.; Khandare, J. J.; Pozharov, V. P.; Minko, T. Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumorspecific treatment and imaging? J. Control. Release, 2008, 130, 107-114.
172. Ni, S.; Fan, X.; Wang, J.; Qi, H.; Li, X. Biodegradable Implants Efficiently Deliver Combination of Paclitaxel and Temozolomide to Glioma C6 Cancer Cells In Vitro. Ann. Biomed. Eng., 2014, 42(1), 214-221.
173. Ranganath, S. H.; Wang, C.-H., Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials, 2008, 29(20), 2996-3003.
174. Winternitz, C. I.; Jackson, J. K.; Oktaba, A. M.; Burt, H. M. Development of a polymeric surgical paste formulation for taxol. Pharm. Res., 1996, 13, 368-375.
175. Farb, A.; Heller, P. F.; Shroff, S.; Cheng, L.; Kolodgie, F. D.; Carter, A. J.; Scott, D. S.; Froehlich, J.; Virmani, R. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation, 2001, 104, 473-479.
176. Ong, B.; Ranganath, S. H.; Lee, L. Y.; Lu, F.; Lee, H. S.; Sahinidis, N.V.; Wang, C.H., Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials, 2009, 30, 3189-3196.
177. Zhang, X.; Jackson, J. K.; Wong, W.; Min, W.; Cruz, T.; Hunter, W. L.; Burt, H. M. Development of biodegradable polymeric paste formulations for taxol: An in vitro and in vivo study. Int. J. Pharm., 1996, 137, 199-208.
178. Burt, H. M.; Jackson, J. K.; Bains, S. K.; Liggins, R. T.; Oktaba, A. M. C.; Arsenault, A.L.; Hunter, W.L. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d, l-lactic acid). Cancer Lett., 1995, 88, 73-79.
179. Jang, S.H.; Wientjes, M.G.; Au, J. L. S. Kinetics of P-glycoproteinmediated efflux of paclitaxel. J. Pharmacol. Exp. Ther., 2001, 298, 1236-1242.
180. Mu, L.; Feng, S. A novel controlled release formulation for the anticancer drug. J. Control. Release, 2003, 86, 33-48.
181. Zhao, L.; Feng, S. S. Enhanced oral bioavailability of paclitaxel formulated in vitamin E[1]TPGS emulsified nanoparticles of biodegradable polymers: In vitro and in vivo studies. J. Pharm. Sci., 2010, 99, 3552-3560.
182. Zhang, Z.; Lee, S. H.; Gan, C. W.; Feng, S. S. In vitro and in vivo investigation on PLA–TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm. Res., 2008, 25, 1925-1935.
183. [183] Win, K. Y.; Feng, S. S. In vitro and in vivo studies on vitamin E TPGS-emulsified poly (D, L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials, 2006, 27, 2285-2291.
184. Yin, W.K.; Feng, S. S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials, 2005, 26, 2713-2722.
185. Zhang, Z.; Feng, S. S. Self-assembled nanoparticles of poly (lactide)– vitamin E TPGS copolymers for oral chemotherapy. Int. J. Pharm., 2006, 324, 191-198.
186. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar over comes tumor drug resistance. J. Control. Release, 2009,136 (1), 21-29.
187. Chen, H.; Zhang, Z.; McNulty, C.; Olbert, C.; Yoon, H. J.; Lee, J. W.; Kim, S. C.; Seo, M. H.; Oh, H. S.; Lemmo, A. V. A highthroughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation. Pharm. Res., 2003, 20, 1302-1308.
188. Gao, P.; Rush, B. D.; Pfund, W. P.; Huang, T.; Bauer, J. M.; Morozowich, W.; Kuo, M. S.; Hageman, M. J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci., 2003, 92, 2386-2398.
189. Gursoy, N.; Garrigue, J. S.; Razafindratsita, A.; Lambert, G.; Benita, S. Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system. J. Pharm. Sci., 2003, 92, 2411-2418.
190. Khandavilli, S.; Panchagnula, R. Nanoemulsions as versatile formulations for paclitaxel delivery: Peroral and dermal delivery studies in rats. J. Invest. Dermatol., 2006, 127, 154-162.
191. Woo, J. S.; Lee, C. H.; Shim, C. K.; Hwang, S. J. Enhanced oral bioavailability of paclitaxel by coadministration of the Pglycoprotein inhibitor KR30031. Pharm. Res., 2003, 20, 24-30.
192. Gao, L.; Liu, G.; Kang, J.; Niu, M.; Wang, Z.; Wang, H.; Ma, J.; Wang, X. Paclitaxel nanosuspensions coated with P-gp inhibitory surfactants: I. Acute toxicity and pharmacokinetics studies. Colloids Surf. B Biointerfaces., 2013, 111, 277-281.
193. Pazdur, R. FDA approval for paclitaxel albumin-stabilized nanoparticle formulation. http://www.cancer.gov/cancertopics/druginfo/fda-nanoparticle-paclitaxel (Accessed June 14, 2013).
194. Miele, E.; Spinelli, G. P.; Miele, E.; Tomao, F.; Tomao, S. Albumin- bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. Int. J. Nanomed., 2009, 4, 99-105.
195. Lee, E.; Lee, J.; Lee, I.-H.; Yu, M.; Kim, H.; Chae, S. Y.; Jon, S. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem., 2008, 51, 6442-6449.
196. Khandare, J. J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, T. Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconjug. Chem., 2006, 17, 1464-1472.
197. Dosio, F.; Arpicco, S.; Stella, B.; Brusa, P.; Cattel, L. Folatemediated targeting of albumin conjugates of paclitaxel obtained through a heterogeneous phase system. Int. J. Pharm., 2009, 382, 117-123.
198. Bradley, M. O.; Webb, N. L.; Anthony, F. H.; Devanesan, P.; Witman, P. A.; Hemamalini, S.; Chander, M. C.; Baker, S. D.; He, L.; Horwitz, S. B., Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res., 2001, 7, 3229-3238.
199. Safavy, A.; Bonner, J. A.; Waksal, H. W.; Buchsbaum, D. J.; Gillespie, G. Y.; Khazaeli, M.; Arani, R.; Chen, D. T.; Carpenter, M.; Raisch, K. P. Synthesis and Biological Evaluation of Paclitaxel- C225 Conjugate as a Model for Targeted Drug Delivery1. Bioconjug. Chem., 2003, 14, 302-310.
200. Jaime, J.; Pagé, M. Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro. Anticancer Res., 2001, 21, 1119-1128.
201. Iqbal, J.; Sarti, F.; Perera, G.; Bernkop-Schnurch, A. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials 2011, 32, 170-175.
202. Teow, H. M.; Zhou, Z.; Najlah, M.; Yusof, S. R.; Abbott, N. J.; Emanuele, A. Delivery of Paclitaxel Across Cellular Barriers Using a Dendrimer-based Nanocarrier. Int. J. Pharm., 2013, 441, 701-711.
203. Arpicco, S.; Stella, B.; Schiavon, O.; Milla, P.; Zonari, D.; Cattel, L. Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives. Int. J. Pharm., 2013, 454(2), 653-659.
204. Montagner, I. M.; Banzato, A.; Zuccolotto, G.; Renier, D.; Campisi, M.; Bassi, P.; Zanovello, P.; Rosato, A. Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines. Urol. Oncol., 2013, 31(7), 1261-1269.
205. Wei, W.; Lv, P.-P.; Chen, X.-M.; Yue, Z.-G.; Fu, Q.; Liu, S.-Y.; Yue, H.; Ma, G.-H., Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials, 2013, 34 (15), 3912-3923.
206. Yu, Y. H.; Kim, E.; Park, D. E.; Shim, G.; Lee, S.; Kim, Y. B.; Kim, C.-W.; Oh, Y.-K., Cationic solid lipid nanoparticles for codelivery of paclitaxel and siRNA. Eur. J. Pharm. Biopharm., 2012, 80(2), 268-273.
207. Jang, Y.L.; Yun, U.J.; Lee, M.S.; Kim, M.G.; Son, S.; Lee, K.; Chae, S. Y.; Lim, D. W.; Kim, H. T.; Kim, S. H. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int. J. Pharm., 2012, 434 (1), 488-493.
208. www.clinicaltrials.gov (Accessed June 14, 2013).